Consequences of a high phosphorus intake on mineral metabolism and bone remodeling in dependence of calcium intake in healthy subjects – a randomized placebo-controlled human intervention study

Table 5 Mean concentrations of plasma and serum hormones and bone metabolism markers during the study periods

Parameter	P1000/Ca0	P1000/Ca500	P1000/Ca1000
Serum 1,25(OH)2D [pmol/l]
Placebo	123.6^a +31.9	118.2±37.3	118.1±30.9
4 weeks	126.7^ab±32.1	132.5±45.3	122.3±39.3
8 weeks	143.8^b±31.5	138.0±47.2	123.6±44.4
Serum 25(OH)D [nmol/l]
Placebo	59.3^a±20.7	60.8^a±20.0	64.0^ab+/-36.8
4 weeks	66.7^a±18.3	64.9^a±16.4	62.7^a±24.7
8 weeks	83.1^b±19.6	82.7^b±22.5	81.0^b±31.1
Plasma PTH [ng/l]
Placebo	20.0±8.1	26.2±11.8	22.2±7.0
4 weeks	20.7±6.6	24.1±7.3	21.1±6.4
8 weeks	21.0±6.7	25.7±9.5	19.9±8.2
Serum osteocalcin [ng/ml]
Placebo	27.6±9.1	29.7^a±11.3	26.6^a±8.6
4 weeks	25.8±9.0	27.8^ab±12.1	23.4^ab±7.8
8 weeks	25.3±9.2	25.0^b±11.7	22.3^b±9.0
Serum BAP [ng/ml]
Placebo	11.1±4.3	10.4^a±2.9	11.4^a±6.8
4 weeks	10.7±4.3	9.1^b±2.5	10.1^b±5.7
8 weeks	10.6±4.4	9.6^ab±2.8	9.6^b±5.4
Plasma CTX [ng/ml]
Placebo	0.58±0.25	0.54^a±0.18	0.52^a±0.21
4 weeks	0.63±0.33	0 49^ab±0.23	0.42^b±0.20
8 weeks	0.60±0.31	0.44^b±0.20	0.43^b±0.22
Plasma P1NP [ng/ml]
Placebo	64.77±32.31	61 13±31.47	54.44±16.68
4 weeks	65.16±30.0	63.58±32.48	56.85±24.09
8 weeks	65.61±29.69	57.67±32.25	52.33±19.26
Urine DPD [pmol/mol Creatinine]
Placebo	3.9±1.7	4.4±2.6	4.3±1.7
4 weeks	4.1±1.7	3.9±1.1	3.9±1.5
8 weeks	3.9±1.4	3.7±1.0	3.9±1.4

n = 58 for plasma P1NP and CTX; n = 60 for 25(OH)D; n = 61 for plasma osteocalcin. BAP. PTH and serum 1.25(OH)₂D; n = 62 for urine DPD; data are expressed as mean ± standard deviation; BAP: bone specific alkaline phosphatase; CTX: cross-linked C-terminal telopeptide of type I collagen; DPD: desoxypyridinoline; PTH: parathyroid hormone; P1NP: N-terminal propeptide of type I procollagen; P1000/Ca0: 1000 mg phosphorus/0 mg calcium; P1000/Ca500: 1000 mg phosphorus/500 mg calcium; P1000/Ca1000: 1000 mg phosphorus/1000 mg calcium; 25(OH)D: 25-hydroxycholecalciferol; 1.25(OH)₂D: 1α,25-dihydroxycholecalciferol; ^{a b} mean values within a column with dissimilar superscript lower case letters are significantly different (p ≤ 0.05); effect of time was tested using general linear model with repeated measurements (with pairwise comparisons based on Bonferroni)

ISSN: 1475-2891